Document Classification

Section Type: METHODS

Text: Fenofibrate/ezetimibe was more effective than either fenofibrate or ezetimibe in reducing LDL-C (-36. 2 % vs -22. 4 % and -22. 8 %, respectively), non-HDL-C (-36. 2 % vs -24. 8 % and -20. 9 %, respectively), total cholesterol (TC) [-27. 9 % vs -18. 9 % and -17. 1 %, respectively], apolipoprotein B (-33. 3 % vs -24. 5 % and -18. 7 %, respectively), TC/HDL-C ratio (-34. 2 % vs -23. 0 % and -17. 0 %, respectively), and apolipoprotein B/apolipoprotein AI ratio (-37. 5 % vs -27. 0 % and -17. 7 %, respectively) [p < 0. 001 for all comparisons between fenofibrate/ezetimibe and monotherapies].